Citius Pharmaceuticals logo

Citius PharmaceuticalsNASDAQ: CTXR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 October 2014

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$66.69 M
-76%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 25 Oct 2024 23:56:01 GMT
$0.37+$0.03(+7.33%)

Dividend

No data over the past 3 years
$15.87 M$15.87 M

Analysts recommendations

Institutional Ownership

CTXR Latest News

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
prnewswire.com05 September 2024 Sentiment: POSITIVE

CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
prnewswire.com12 August 2024 Sentiment: POSITIVE

Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024, under ticker CTOR Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter 2024 ended June 30, 2024.

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
prnewswire.com12 August 2024 Sentiment: POSITIVE

LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition ("TenX") (Nasdaq: TENK), a publicly traded special purpose acquisition company.

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
prnewswire.com12 August 2024 Sentiment: POSITIVE

Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments.

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
prnewswire.com05 August 2024 Sentiment: POSITIVE

Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J. , Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane Acquisition ("TenX") (Nasdaq: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination with Citius Pharma's oncology subsidiary.

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
newsfilecorp.com18 July 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.

Analysts Hunt for Undervalued Biotech Stocks
newsfilecorp.com17 July 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.

Biopharma Stocks Transformative Innovation for the Future of Health
newsfilecorp.com11 July 2024 Sentiment: POSITIVE

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
prnewswire.com10 July 2024 Sentiment: POSITIVE

Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approved First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantage Financial platform and pending oncology spin-off support pipeline development and investment in long-term growth Clinical and operational achievements offer powerful levers for value creation National Sales Director onboarded to recruit and lead the sales organization in preparation for anticipated launch of LYMPHIR CRANFORD, N.J. , July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date Leonard Mazur, Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months.

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
prnewswire.com29 May 2024 Sentiment: POSITIVE

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.

What type of business is Citius Pharmaceuticals?

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

What sector is Citius Pharmaceuticals in?

Citius Pharmaceuticals is in the Healthcare sector

What industry is Citius Pharmaceuticals in?

Citius Pharmaceuticals is in the Biotechnology industry

What country is Citius Pharmaceuticals from?

Citius Pharmaceuticals is headquartered in United States

When did Citius Pharmaceuticals go public?

Citius Pharmaceuticals initial public offering (IPO) was on 02 October 2014

What is Citius Pharmaceuticals website?

https://citiuspharma.com

Is Citius Pharmaceuticals in the S&P 500?

No, Citius Pharmaceuticals is not included in the S&P 500 index

Is Citius Pharmaceuticals in the NASDAQ 100?

No, Citius Pharmaceuticals is not included in the NASDAQ 100 index

Is Citius Pharmaceuticals in the Dow Jones?

No, Citius Pharmaceuticals is not included in the Dow Jones index

When was Citius Pharmaceuticals the previous earnings report?

No data

When does Citius Pharmaceuticals earnings report?

The next expected earnings date for Citius Pharmaceuticals is 14 February 2025